{"id":2371,"date":"2025-09-26T11:06:16","date_gmt":"2025-09-26T10:06:16","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=2371"},"modified":"2025-09-26T11:06:17","modified_gmt":"2025-09-26T10:06:17","slug":"new-hope-for-er-advanced-breast-cancer-roches-giredestrant-everolimus-combo-shows-significant-pfs-improvement","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/uncategorised\/new-hope-for-er-advanced-breast-cancer-roches-giredestrant-everolimus-combo-shows-significant-pfs-improvement\/","title":{"rendered":"New Hope for ER+ Advanced Breast Cancer: Roche\u2019s Giredestrant\/Everolimus Combo Shows Significant PFS Improvement"},"content":{"rendered":"\n

<\/p>\n\n\n\n

\n\n\n\n

Major Step Forward in Endocrine-Resistant Breast Cancer Treatment<\/strong><\/h2>\n\n\n\n

Roche has announced positive results from its Phase III evERA study<\/strong>, signaling a potential new treatment option for patients with Estrogen Receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer<\/strong> whose disease has progressed following prior treatment with a CDK4\/6 inhibitor and endocrine therapy.<\/p>\n\n\n\n

The study found that the combination of the investigational oral drug giredestrant<\/strong> with everolimus<\/strong> achieved a statistically significant and clinically meaningful improvement<\/strong> in Progression-Free Survival (PFS)<\/strong> compared to the standard of care endocrine therapy plus everolimus. This benefit was observed across both the overall study population and in patients whose tumors carried the challenging ESR1 mutation<\/strong>.<\/p>\n\n\n\n

“This data is highly encouraging,” says [Insert Qualified Author\/Reviewer Name, e.g., Dr. Jane Doe, Oncologist]. “It validates the strategy of combining a next-generation therapy like giredestrant with a well-established agent like everolimus to overcome resistance, particularly in the difficult-to-treat post-CDK inhibitor setting.”<\/p>\n\n\n\n

Understanding the Significance of Giredestrant<\/strong><\/h3>\n\n\n\n

Giredestrant is an oral, next-generation Selective Estrogen Receptor Degrader (SERD)<\/strong> and a full antagonist. Its mechanism of action is crucial in combating endocrine resistance:<\/p>\n\n\n\n

    \n
  1. Blocking Estrogen:<\/strong> Giredestrant actively blocks estrogen from binding to the ER.<\/li>\n\n\n\n
  2. Degradation:<\/strong> Critically, it then triggers the breakdown (degradation)<\/strong> of the estrogen receptor itself.<\/li>\n<\/ol>\n\n\n\n

    Unlike older endocrine therapies, this dual action can be highly effective against resistance mechanisms, including the common ESR1 mutations<\/strong>, which can cause the ER to signal independently of estrogen.<\/p>\n\n\n\n

    Why This Oral Combination Matters to Patients<\/strong><\/h3>\n\n\n\n

    The evERA study is notable because it is the first positive head-to-head Phase III trial<\/strong> investigating an all-oral SERD-containing regimen<\/strong> against a standard-of-care combination.<\/p>\n\n\n\n

    For patients, an all-oral treatment offers significant quality-of-life benefits:<\/p>\n\n\n\n